Filter the drugs by their COVID-19 status ,phase of research and how they help

COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. Browse the database of potential drugs for COVID-19 treatment compiled by the AIM tool.
Substance COVID-19 status Phase of research How it helps Latest publication 
FN3D
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/05/2021
FN3B
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/05/2021
FN3A
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/05/2021
FN3C
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/05/2021
ELI-005
Potential treatment - pre-clinical evidence Experimental Vaccine Feb/05/2021
DREP-S
Potential treatment - pre-clinical evidence Experimental Vaccine Feb/04/2021
DREP-Secto
Potential treatment - pre-clinical evidence Experimental Vaccine Feb/04/2021
Rac5c
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/04/2021
mRNA-RBD
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/03/2021
LbuCas13a N3.2
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/03/2021
MVA/S
Potential treatment - pre-clinical evidence Experimental Vaccine Feb/03/2021
Valrubicin
Potential treatment - theoretical effect Experimental Antiviral Feb/02/2021
5-(Acryloylamino)-2-methyl-N-[(1R)-1-(naphthalen-1-yl)ethyl]benzamide
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/02/2021
5-[(Carbamoylcarbamoyl)amino]-2-methyl-N-[(1R)-1-(naphthalen-1-yl)ethyl]benzamide
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/02/2021
5-pentanoylamino-2-methyl-N-[(1R)-1-naphthalen-1-ylethyl]benzamide
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/02/2021
5-(((4-nitrophenoxy)carbonyl)amino)-2-methyl-N-[(1R)-1-naphthalen-1-ylethyl]benzamide
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/02/2021
5-(butylcarbamoylamino)-2-methyl-N-[(1R)-1-naphthalen-1-ylethyl]benzamide
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/02/2021
3-amino-N-(naphthalene-1-yl)-5-trifluoromethyl)benzamide
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/02/2021
Infliximab
Potential treatment - clinical evidence Experimental Antiviral Feb/01/2021
ACE2 1–618-ABD
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/01/2021